Filing Flows › Health Care › Regenxbio (RGNX)
Regenxbio (RGNX) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Regenxbio (RGNX) Q3 2026 earnings results →
Q3 2026 Revenue down 69% year over year to $9.2M · 445¢ of every $1 of revenue lost · operating margin -387.8%
Regenxbio made $9.2M in Q3 2026 (-69% Y/Y): License and Service $5.2M, Service $3.9M. Operating margin -387.8%, net loss $40.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $9.2M in Q3 2026, down 69% year over year and down 92% from the previous quarter. Nippon Shinyaku Services was the largest line at 36% of revenue. Zolgensma Royalties lost $21.2M year over year (down 90%), 103% of the total change.
Operating costs exceeded revenue by $35.5M, an operating margin of -387.8%. Total costs fell 46% while revenue fell 69%. The quarter ended with a net loss of $40.7M, after a profit of $22.7M the previous quarter.
Operating cash flow was $38.6M. Non-cash charges added back $3.5M of depreciation and amortization and $8.1M of share-based compensation. Working capital and other items added $67.7M. Capital expenditures of $194K left free cash flow of $38.4M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $9.2M | -69% | -387.8% | −$40.7M | $38.6M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $108M | +406% | 27.1% | $22.7M | −$62.2M |
| Q1 2026 | 10-Q | May 14, 2026 | $6.4M | -93% | n/m | −$90.1M | −$76.2M |
| Q4 2025 | 10-K | Mar 5, 2026 | $30.3M | +43% | -190.0% | −$67.1M | −$52.3M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $29.7M | +23% | -176.3% | −$61.9M | −$56.0M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $21.4M | -4% | -296.3% | −$70.9M | −$49.3M |
| Q1 2025 | 10-Q | May 12, 2025 | $89.0M | +470% | 13.6% | $6.1M | $33.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
About Regenxbio
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie, and NAVSUNLI™ (clemidsogene lanparvovec-sngl, RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA ® . REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people.
In its own words, from its 8-K, filed Aug 6, 2026.
Regenxbio against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -69% against the peers' median +11%. Operating margin: -387.8% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| RGNX Regenxbio | Q3 2026 | $9.2M | -69% | -387.8% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Regenxbio 10-Q on SEC EDGAR · CIK 1590877 · Biological Products, (No Diagnostic Substances)
Guidance and outlook
13F: who owns RGNX and who is buying
More on RGNX
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results